NCT01757457View on ClinicalTrials.gov

Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Myocardial Infarction
Interventions
DRUG

Intracoronary administration of an abciximab bolus during primary PCI

Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI

DRUG

Intravenous administration of an abciximab bolus during primary PCI

Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI

Trial Locations (1)

28100

Ospedale Maggiore della Carità, Novara

All Listed Sponsors
lead

Azienda Ospedaliero Universitaria Maggiore della Carita

OTHER

NCT01757457 - Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter